Celularity, Inc. (NASDAQ:CELU) Sees Significant Drop in Short Interest

Key Points

• Celularity, Inc. experienced a significant 54.3% decrease in short interest in September, dropping from 1,400,000 shares to 640,100 shares.
• The company reported a loss of ($1.02) EPS for its last quarter, with a revenue of $5.74 million and a negative net margin of 165.22%.
• Analysts have mixed views on Celularity, with WBB Securities upgrading it to a "buy" with a target price of $6.00, while Weiss Ratings maintains a "sell" rating.

Celularity, Inc. (NASDAQ:CELU - Get Free Report) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totaling 640,100 shares, a decrease of 54.3% from the September 15th total of 1,400,000 shares. Based on an average daily trading volume, of 278,900 shares, the days-to-cover ratio is presently 2.3 days. Approximately 4.3% of the shares of the stock are short sold. Approximately 4.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 278,900 shares, the days-to-cover ratio is presently 2.3 days.

Celularity Price Performance

Celularity stock opened at $1.98 on Monday. The firm has a 50 day simple moving average of $2.66 and a 200-day simple moving average of $2.30. The stock has a market cap of $52.85 million, a price-to-earnings ratio of -0.62 and a beta of 0.75. Celularity has a 1-year low of $1.00 and a 1-year high of $5.22.

Celularity (NASDAQ:CELU - Get Free Report) last released its quarterly earnings data on Friday, August 29th. The company reported ($1.02) EPS for the quarter. The business had revenue of $5.74 million during the quarter. Celularity had a negative net margin of 165.22% and a negative return on equity of 459.57%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CELU shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Celularity in a research note on Wednesday, October 8th. WBB Securities upgraded Celularity from a "hold" rating to a "buy" rating and set a $6.00 target price on the stock in a report on Tuesday, September 9th. Finally, Wall Street Zen lowered Celularity from a "hold" rating to a "sell" rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Celularity has an average rating of "Hold" and a consensus price target of $6.00.

Hedge Funds Weigh In On Celularity

Hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC purchased a new stake in Celularity in the 1st quarter valued at about $34,000. XTX Topco Ltd increased its position in shares of Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock valued at $42,000 after acquiring an additional 11,057 shares during the last quarter. Bank of America Corp DE increased its position in shares of Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock valued at $73,000 after acquiring an additional 35,023 shares during the last quarter. Finally, Valmark Advisers Inc. purchased a new stake in shares of Celularity in the 2nd quarter valued at approximately $98,000. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.